United States Influenza Vaccines Market: Focus on Persons Vaccinated, Pricing, Production, Supply, Promising Influenza Vaccines, Clinical Trials, Regulatory, Reimbursement, Distribution Channel, Major Deals, Key Players, Recent Developments – Size, Share, Trends, Analysis, Demand, Opportunity, and Forecast, 2022 – 2030

The United States Influenza Vaccines market size is expected to reach USD 7,007 million by 2030. It is expected to expand at a CAGR of 6.9% from 2021 to 2030.

This new market report offerings an wide-ranging study of the entire United States influenza vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States influenza vaccines market. The report also provides up-to-date market size data for the period 2015 - 2021 and an illustrative forecast to 2030 covering key market aspects like market value and volume for influenza vaccines.

This Newest and Comprehensive United States Influenza Vaccines Market Research Report 2022 Delivers:

The United States Influenza Vaccines Market Size, Insights, Analysis and Forecast,2015-2030
The United States Number of Persons Vaccinated with Influenza Vaccines and Forecast, 2015 - 2030
Analyzes the United States Children Being Vaccinated with Influenza Vaccines and Forecast,2015 - 2030
Analyzes the United States Adults Being Vaccinated with Influenza Vaccines and Forecast, 2015 - 2030
Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market
The United States Influenza Vaccines Pricing Analysis, Trends and Insights
The United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
The United States Influenza Vaccines Distribution and Demand Analysis (2010 - 2021)
Examines the Effectiveness of the Influenza Vaccines in the United States (2004 2021)
Thoroughly Evaluates Rapid Diagnostic Testing for the Management of Influenza
Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States
Reimbursement Environment of the United States Influenza Vaccines Market
Regulatory Framework of the United States Influenza Vaccines Market
Major Deals and Agreement Activities in the Influenza Vaccines Market
An Insightful Analysis of the Promising Influenza Vaccines in the Clinical Development
Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2020 and 2021
A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development
An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

The Major and Emergent Market Players for the U.S Influenza Vaccines Market are Listed Below :

Sanofi Pasteur
GlaxoSmithKline (GSK)
Seqirus (CSL Limited)
AstraZeneca
Novavax
BiondVax Pharmaceuticals Ltd.
Medicago
Moderna Inc
Pneumagen
DaiichiSankyo
Altimmune
FluGen
Imutex
Versatope Therapeutics, Inc
EpiVax, Inc

Key Questions Answered by this Latest 2022 Report:

What is the current scenario of the U.S. influenza vaccines market?
What is the total market size and forecast (until 2030) for the U.S. influenza vaccines market?
How many persons being vaccinated with influenza vaccines in the US during 2015 2027?
How effective is influenza(flu) shot for 2021?
What percentage of the United States do people get the flu vaccine?
What are the key marketed influenza vaccines available in the United States?
What are the major drivers of the United States influenza vaccines market?
What are the major inhibitors of the United States influenza vaccines market?
What is the reimbursement pattern in the United States influenza vaccines market?
What is the regulatory framework in the United States influenza vaccines market?
What are the major deals and agreement happenings in the United States influenza vaccines market?
What are the upcoming influenza vaccines that will have a significant impact on the market in the future?
Who are the top market players? What are their happenings, vaccine revenue, current developments, and scenarios?
Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?
How is the market predicted to develop in the future?

1. Executive Summary

2. United States Influenza Vaccines Market Size, Insights, Analysis and Forecasts (2015 - 2030)

3. United States Number of Persons Vaccinated with Influenza Vaccines (2015 - 2030)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines

4. Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Challenges

5. United States Influenza Vaccines Pricing Analysis, Trends and Insights

6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)

7. United States Influenza Vaccines Distribution and Demand Analysis (2010 - 2021)

8. Effectiveness of Influenza Vaccines in the United States (2004 2021)

9. Rapid Diagnostic Testing for the Management of Influenza

10. Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States

11. Reimbursement Environment of the United States Influenza Vaccines Market

12. Regulatory Framework of the United States Influenza Vaccines Market

13. Major Deals and Agreement Activities in the Influenza Vaccines Market
13.1 Merger and Acquisitions
13.2 Collaboration Deals
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement

14. Promising Influenza Vaccines in the Clinical Development

15. Influenza Vaccines Clinical Trial Insights by Phase, Company and Country
15.1 Year 2021
15.2 Year 2020

16. Key Players Analysis
16.1 Sanofi Pasteur
16.1.1 Business Overview
16.1.2 Influenza Vaccines Portfolio
16.1.3 Influenza Vaccines Sales Value Analysis
16.1.4 Promising Influenza Vaccines in the Clinical Development
16.1.5 Recent Development
16.2 GlaxoSmithKline (GSK)
16.2.1 Business Overview
16.2.2 Influenza Vaccines Portfolio
16.2.3 Influenza Vaccines Sales Value Analysis
16.2.4 Recent Development
16.3 Seqirus
16.3.1 Business Overview
16.3.2 Influenza Vaccines Portfolios
16.3.3 Influenza Vaccines Sales Value Analysis
16.3.4 Promising Influenza Vaccines in the Clinical Development
16.3.5 Recent Development
16.4 AstraZeneca
16.4.1 Business Overview
16.4.2 Influenza Vaccines Portfolio
16.4.3 Influenza Vaccines Sales Value Analysis
16.4.4 Recent Development

17. Emerging Players Analysis
17.1 Novavax
17.1.1 Business Overview
17.1.2 Promising Influenza Vaccines in the Clinical Development
17.1.3 Recent Development
17.2 BiondVax Pharmaceuticals Ltd.
17.2.1 Business Overview
17.2.2 Promising Influenza Vaccines in the Clinical Development
17.2.3 Recent Development
17.3 Medicago
17.3.1 Business Overview
17.3.2 Promising Influenza Vaccines in the Clinical Development
17.3.3 Recent Development
17.4 Moderna Inc
17.4.1 Business Overview
17.4.2 Promising Influenza Vaccines in the Clinical Development
17.4.3 Recent Development
17.5 Pneumagen
17.5.1 Business Overview
17.5.2 Promising Influenza Vaccines in the Clinical Development
17.5.3 Recent Development
17.6 Altimmune
17.6.1 Business Overview
17.6.2 Promising Influenza Vaccines in the Clinical Development
17.6.3 Recent Development
17.7 Daiichi Sankyo
17.7.1 Business Overview
17.7.2 Promising Influenza Vaccines in the Clinical Development
17.7.3 Recent Development
17.8 FluGen
17.8.1 Business Overview
17.8.2 Promising Influenza Vaccines in the Clinical Development
17.8.3 Recent Development
17.9 Imutex
17.9.1 Business Overview
17.9.2 Promising Vaccines in the Clinical Development
17.9.3 Recent Development
17.10 EpiVax
17.10.1 Business Overview
17.10.2 Promising Influenza Vaccines in the Clinical Development
17.10.3 Recent Development
17.11 Versatope Therapeutics, Inc.
17.11.1 Business Overview
17.11.2 Promising Influenza Vaccines in the Clinical Development
17.11.3 Recent Development

List Of Tables

Table 51: United States Pediatric Influenza Vaccines Price, 2021 2022
Table 52: United States Adult Influenza Vaccines Price, 2021 2022
Table 61: United States Influenza Vaccines Production, Supply, and Allocation
Table 71: Total Percentage of Influenza Vaccines Released by Week, 2021 2022
Table 71: Total Percentage of Influenza Vaccines Released by Week, 2020 2021
Table 72: Total Percentage of Influenza Vaccines Released by Week, 2019 2020
Table 73: Total Percentage of Influenza Vaccines Released by Week,2018 2019
Table 74: Total Percentage of Influenza Vaccines Released by Week,2017 2018
Table 75: Total Percentage of Influenza Vaccines Released by Week,2016 2017
Table 76: Total Percentage of Influenza Vaccines Released by Week,2015 2016
Table 77: Total Percentage of Influenza Vaccines Released by Week,2014 2015
Table 81: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 2021
Table 91: Influenza Virus Testing Methods
Table 101: Distribution of Influenza Vaccination
Table 121: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 131: Merger & Acquisitions in the Influenza Vaccines Market
Table 132: Collaboration Deal in the Influenza Vaccines Market
Table 133: Licensing Agreement in the Influenza Vaccines Market
Table 134: Exclusive Agreement in the Influenza Vaccines Market
Table 135: Distribution Agreement in the Influenza Vaccines Market
Table 141: BiondVax Pharmaceuticals Ltd. Clinical Trials
Table 161: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 162: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 171: Novavax Promising Influenza Vaccines in the Clinical Development
Table 172: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 173: Medicago Promising Influenza Vaccines in the Clinical Development
Table 174: Moderna Promising Influenza Vaccines in the Clinical Development
Table 175: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 176: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 177: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 178: FluGen Promising Influenza Vaccines in the Clinical Development
Table 179: Imutex Promising Influenza Vaccines in the Clinical Development
Table 1210: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 1211: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development

List Of Figures

Figure 21: United States Influenza Vaccines Market Size and Analysis (Million US$),2015 2021
Figure 22: United States Influenza Vaccines Market Size and Forecast (Million US$),2022 2030
Figure 31: United States Total Number of Individuals Vaccinated with Influenza Vaccines (Thousand), 2015 2021
Figure 32: United States Total Number of Individuals Vaccinated with Influenza Vaccines Forecast (Thousand), 2022 2030
Figure 33: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2015 2021
Figure 34: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2022 2030
Figure 35: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2015 2021
Figure 36: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2022 2030
Figure 71: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 2021
Figure 101: United States Place of Influenza Vaccination for Children and Adults (Percent),2019 - 2020
Figure 161: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2015 2021
Figure 162: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2022 2030
Figure 163: GSK Influenza Vaccines Net Sales Value (Million US$),2015 2021
Figure 164: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2022 2030
Figure 165: Seqirus Influenza Vaccines Net Sales Value (Million US$),2015 2021
Figure 166: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2022 2030
Figure 167: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2015 2021
Figure 168: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2022 2030

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available